GM1 gangliosidosis is an incurable glycosphingolipid (GSL) lysosomal storage disease caused by a genetic deficiency in lysosomal acid ␤ -galactosidase ( ␤ -gal) and leads to the storage of II 3 NeuAc-GgOse 4 Cer (GM1) and its asialo derivative (GA1) in the central nervous system (CNS) (1) .
Age of onset ranges from infancy to adulthood, and excessive CNS ganglioside accumulation produces progressive neurodegeneration and brain dysfunction in humans. A ␤ -gal-deficient mouse model of GM1 gangliosidosis was generated using homologous recombination and embryonic stem cell technology (2) . We recently showed that these mice accumulate GM1 and GA1 in the brain as early as postnatal day 5 (p-5), thus mimicking the neurochemical features of the infantile disease form (3) . In contrast to infantile-onset patients, in whom ganglioside accumulation leads to behavioral and developmental abnormalities within the first few years of life, ␤ -gal-deficient mice are phenotypically indistinguishable from normal mice until adult ages (2) .
Most therapies for ganglioside storage diseases focus on augmenting lysosomal enzyme levels and involve bone marrow transplantation, enzyme replacement, stem cell therapy, gene therapy, and chemical chaperone therapy (4) (5) (6) (7) (8) (9) (10) (11) . These therapeutic approaches, however, have difficulty reducing GSL storage products throughout the CNS. Alternatively, substrate reduction therapy, originally proposed by Radin (12) and others (13) (14) (15) (16) (17) , aims to reduce GSL synthesis to counterbalance the impaired rate of catabolism, thus reducing GSL accumulation and disease progression. Platt and colleagues (15, (18) (19) (20) (21) used this therapy to treat adult-onset ganglioside storage disease in mice more recently. We recently provided evidence that substrate reduction therapy using N -butyldeoxygalactonojirimycin ( N B-DGJ) could significantly reduce total brain ganglioside and GM1 content in neonatal normal and ␤ -gal-deficient mutant mice (3) .
The imino sugars N -butyldeoxynojirimycin ( N B-DNJ) and N B-DGJ are competitive inhibitors of the ceramidespecific glucosyltransferase that catalyzes the first step in GLS biosynthesis (15) . Substrate reduction therapy using N B-DNJ and N B-DGJ have successfully reduced brain ganglioside content, delayed symptom onset, and increased survival in adult mouse models of the GM2 gangliosidoses (Tay-Sachs disease and Sandhoff disease) (13, 17, 22) . N B-DNJ is also approved for the treatment of type 1 Gaucher disease (glucosylceramide storage) and is under trial evaluation for late-onset Tay-Sachs disease (23) (24) (25) . N B-DGJ, however, may be more suitable for treating neonates than N B-DNJ, because digestive abnormalities and weight loss do not occur with N B-DGJ treatment (3, 17, 26) . Furthermore, we previously showed that N B-DGJ could reduce GSL and ganglioside biosynthesis by 90% in normal mouse embryos without impairing viability, growth, or morphogenesis (27) . Our studies in embryonic and neonatal mice suggest that N B-DGJ may be an effective early intervention therapy for the gangliosidoses.
In this study, we investigated for the first time the effects of N B-DGJ in normal C57BL/6J (B6) mice and ␤ -gal-deficient ( ␤ -gal Ϫ / Ϫ ) mutant mice from p-9 to p-15. This is a period of most active cerebellar development and CNS myelinogenesis in the mouse involving the proliferation and migration of granule cells, synaptogenesis, and the rapid accumulation of cerebroside, a myelin-enriched GSL (28-31) Also, this developmental period is comparable to latestage embryonic and early development in humans (32, 33) . Our results show that N B-DGJ significantly reduces cerebrum-brainstem (C-BS) and cerebellar total ganglioside and GM1 content during this critical developmental period. Moreover, no adverse effects of the drug treatment were observed in the normal or mutant mice for cerebellar growth and morphology or brain cerebroside content.
MATERIALS AND METHODS

Mice
The B6 mice were obtained from the Jackson Laboratory (Bar Harbor, ME). B6/129Sv mice, heterozygous for the GM1 gene ( ␤ -gal ϩ / Ϫ ), were obtained from Dr. Alessandra d'Azzo (Saint Jude Children's Research Hospital, Memphis, TN). The B6 mice were used as normal controls because this genetic background largely composed that of the knockout mice. The knockout mice were derived by homologous recombination and recombinant stem cell technology as previously described (2) . Homozygous ␤ -gal Ϫ / Ϫ mouse pups were derived from crossing ␤ -gal Ϫ / Ϫ adults, thus ensuring that control and drug-treated ␤ -gal Ϫ / Ϫ pups were compared within the same litter. Likewise, control and drugtreated normal B6 pups were compared within the same litter. Genotypes were determined postmortem by measuring ␤ -gal-specific activity in tail tissue using a modification of the Galjaard procedure (34, 35) . All mice were propagated at the Boston College Animal Facility and were housed in plastic cages with filter tops containing Sani-Chip bedding (P. J. Murphy Forest Products Corp., Montville, NJ). The room was maintained at 22 Њ C on a 12 h light/dark cycle. Food (Prolab RMH 3000; PMI LabDiet, Richmond, IN) and water were provided ad libitum. Cotton nesting pads were provided to nursing females for the duration of the experiment. All animal experiments were carried out with ethical committee approval in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care Committee.
N B-DGJ treatment and tissue collection
N B-DGJ was purchased from Toronto Research Chemicals, Inc. (North York, Ontario, Canada). N B-DGJ solutions were prepared in sterile saline to yield a final concentration of ‫ف‬ 0.2 mg/ l. Postnatal B6 and ␤ -gal Ϫ / Ϫ mice were injected daily intraperitoneally from p-9 to p-15 with either vehicle (0.9% saline) or N B-DGJ at 600 mg/kg body weight. Injections were performed using a Hamilton syringe (26 gauge, point style 2, 0.5 inch needle length), and volumes ranged from ‫ف‬ 10 to 25 l/mouse. Body weights were measured before cervical dislocation ‫ف‬ 4 h after the final injection on p-15. Cerebellum was separated from the C-BS, and the tissues were frozen on dry ice to obtain wet weights. Two or three cerebella were pooled for each B6 sample, but each ␤ -gal Ϫ / Ϫ cerebellum as well as each C-BS was analyzed separately. The samples were frozen at Ϫ 80 Њ C and lyophilized to determine water content. Additional mice were killed by CO 2 asphyxiation for histology. The brains of these mice were exposed after midline resection along the sutures of the skull and were immersed in ‫ف‬ 25 ml of Bouin's fixative (LabChem, Inc., Pittsburgh, PA) for 3 days at room temperature. The brains were then removed from the skull, placed in diluted Bouin's fixative [1:10 with deionized H 2 O (dH 2 O)], and stored at 4 Њ C.
Lipid isolation, purification, and quantitation
Total lipid extraction. Total lipids were isolated and purified from the lyophilized brain tissue using modifications of previously described procedures (3, 35, 36) . Briefly, total lipids were extracted with 5 ml of CHCl 3 and CH 3 OH (1:1, v/v) and 0. Column chromatography. Neutral and acidic lipids were separated using DEAE-Sephadex (A-25; Pharmacia Biotech, Uppsala, Sweden) column chromatography as previously described (37) . DEAE-Sephadex was prepared in bulk by washing the resin three times with solvent B (CHCl 3 /CH 3 OH/0.8 M Na acetate, 30:60:8, v/v), equilibrating in solvent B overnight, followed by washing three times with solvent A until neutral. The total lipid extract, suspended in solvent A, was then applied to a DEAE-Sephadex column (1.2 ml bed volume) that had been equilibrated previously with solvent A. The column was washed twice with 20 ml of solvent A, and the entire neutral lipid fraction, consisting of the initial eluent plus washes, was collected. This fraction contained the following lipids: cholesterol, phosphatidylcholine, phosphatidylethanolamine, plasmalogens, ceramide, sphingomyelin, cerebrosides, and GA1. Next, acidic lipids were eluted from the column with 30 ml of solvent B. This fraction contained the gangliosides and other less hydrophilic acidic lipids.
Ganglioside purification. The acidic lipid fraction containing gangliosides was dried by rotary evaporation and transferred to a 15 ml graduated glass conical tube using CHCl 3 /CH 3 OH (1:1, v/v) and adjusted to 7 ml using the same solvent. Water (2.6 ml) was added and the mixture was inverted, vortexed, and centrifuged for ‫ف‬ 10 min at 1,200 g to partition gangliosides into the upper phase (36, 38) . The upper aqueous phase was removed and the lower organic phase was washed once with 4.5 ml of the Folch pure solvent upper phase (CHCl 3 /CH 3 OH/dH 2 O, 3:48:47, v/v). The combined upper phases, containing the gangliosides, were adjusted to 11 ml using the pure solvent upper phase.
Resorcinol assay. An aliquot of the ganglioside fraction (Folch upper phase) was evaporated under a stream of nitrogen and analyzed for sialic acid content using a modified resorcinol method (39) (40) (41) . N -acetylneuraminic acid (Sigma, St. Louis, MO) was used as an external standard. Samples were dissolved in 1 ml of resorcinol reagent/dH 2 O (1:1, v/v), boiled for 15 min, and then by guest, on October 21, 2017 www.jlr.org Downloaded from cooled in an ice bath. Butyl acetate/1-butanol (1.5 ml; 85:15, v/v) was then added, and the samples were vortexed and centrifuged at 1,200 g . The violet supernatant was removed and analyzed at 580 nm in the Shimadzu UV-1601 ultraviolet-visible spectrophotometer (Shimadzu, Kyoto, Japan).
Base treatment and desalting. After removing the aliquots for the resorcinol assay, the ganglioside fraction was evaporated under a stream of nitrogen and treated with mild base (1 ml of 0.5 M NaOH) in a shaking water bath at 37 Њ C for 1.5 h. Base and salts were separated from the gangliosides using a modification of a previously described method (42) . The sample was applied to a C18 reverse-phase Bond Elute column (Varian, Harbor City, CA) that was equilibrated with 5 ml each of CHCl 3 /CH 3 OH (1:1, v/v), CHCl 3 , and 0.1 M NaCl. The column was washed with 25 ml of dH 2 O to remove salts. Gangliosides were eluted from the column with 2 ml of CHCl 3 followed by 4 ml of CHCl 3 /CH 3 OH (1:1, v/v) and stored at 4 Њ C.
Neutral lipid purification. Neutral lipids were dried by rotary evaporation and resuspended in 10 ml of CHCl 3 /CH 3 OH (2:1, v/v). To further purify GA1, a 4 ml aliquot of the neutral lipid fraction was evaporated under a stream of nitrogen, base treated, and Folch partitioned as described previously and above (3). The Folch lower phase containing GA1 was evaporated under a stream of nitrogen and resuspended in 10 ml of CHCl 3 /CH 3 OH (2:1, v/v).
High-performance thin-layer chromatography. All lipids were analyzed qualitatively by high-performance thin-layer chromatography (HPTLC) according to previously described methods (36, 37, 43) . Lipids were spotted on 10 ϫ 20 cm Silica gel 60 HPTLC plates (E. Merck, Darmstadt, Germany) using a Camag Linomat III auto-TLC spotter (Camag Scientific, Inc., Wilmington, NC). The amount of lipid per lane was equivalent to 1.5 g of total sialic acid for gangliosides and either 0.4 or 0.3 mg of tissue dry weight for GA1 or neutral lipids, respectively. To enhance precision, an internal standard (oleoyl alcohol) was added to the neutral lipid standards and samples as previously described (37) . Purified lipid standards were either purchased from Matreya, Inc. (Pleasant Gap, PA), or Sigma or were a gift from Dr. Robert Yu (Medical College of Georgia, Augusta, GA).
For gangliosides and GA1, the HPTLC plates were developed by a single ascending run with CHCl 3 /CH 3 OH/dH 2 O (55:45:10, v/v for gangliosides; 65:35:8, v/v for GA1) containing 0.02% CaCl 2 ·2H 2 O. The plates were sprayed with either the resorcinolHCl reagent or the orcinol-H 2 SO 4 reagent and heated at 95 Њ C for 30 min to visualize gangliosides or GA1, respectively (39, 44) . For neutral lipids, the plates were developed to a height of 4.5 cm with chloroform-methanol-acetic acid-formic acid-water (35: 15:6:2:1, v/v), dried for ‫ف‬ 20 min, and developed to the top with hexanes-diisopropyl ether-acetic acid (65:35:2, v/v) as previously described (37, 45) . Neutral lipids were visualized by charring with 3% cupric acetate in 8% phosphoric acid solution, followed by heating in an oven at 160-170 Њ C for 7 min.
The percentage distribution and density of the individual bands was determined by scanning the plates on a Personal Densitometer SI with ImageQuant software (Molecular Dynamics, Sunnyvale, CA) for gangliosides and neutral lipids or on a ScanMaker 4800 with ScanWizard5 V7.00 software (Microtek, Carson, CA) for GA1. The total brain ganglioside distribution was normalized to 100%, and the percentage distribution values were used to calculate sialic acid concentration (micrograms of sialic acid per 100 mg dry weight) of individual gangliosides as we previously described (46) . The density values for GA1 and sphingomyelin were fit to a standard curve of the respective lipid and used to calculate individual concentrations expressed as micrograms per 100 mg dry weight.
Histological analysis. The brains stored in diluted Bouin's fixative were embedded in paraffin, sectioned (sagittal, 5 m), and stained with hematoxylin and eosin, Luxol Fast Blue (LFB), and Periodic Acid Schiff (PAS) at the Harvard University Rodent Histopathology Core Facility (Boston, MA). Slides were examined using a Zeiss Axioplane 2 imaging universal microscope and a Hamamatsu Orca-ER digital camera with Openlab software. This equipment was also used to measure external granular layer (EGL) thickness in two cerebellar regions (vernal lobules VI and X) on hematoxylin and eosin-stained sections of control and treated ␤ -gal Ϫ / Ϫ mice. EGL thickness was expressed as the average of 10 measurements per independent sample in which four independent cerebellar samples per group were analyzed.
RESULTS
Our objective was to determine whether substrate reduction therapy using N B-DGJ could reduce C-BS and cerebellar ganglioside content in B6 and ␤ -gal Ϫ / Ϫ mice during a critical period of cerebellar development and myelinogenesis (i.e., from p-9 to p-15). Total ganglioside content was greater in the C-BS than in the cerebellum of both the normal B6 and the mutant mice ( Table 1 ) . Also, total ganglioside content in the C-BS and the cerebellum was higher in the untreated ␤ -gal Ϫ / Ϫ mice than in the untreated B6 mice. Daily N B-DGJ injections from p-9 to p-15 significantly reduced total C-BS ganglioside content by 16% in the B6 mice and by 19% in the ␤ -gal Ϫ / Ϫ mice (Table 1) . Similarly, N B-DGJ reduced total cerebellar ganglioside content by 22% in the B6 mice and by 21% in the ␤ -gal Ϫ / Ϫ mice (Ta- ble 1). C-BS and cerebellar total ganglioside content was actually lower in the ␤-gal Ϫ/Ϫ mice after NB-DGJ treatment than in the untreated B6 mice. The reduction in CNS ganglioside content was not associated with changes in body weight or C-BS/cerebellar weight or water content in either normal or mutant mice ( Table 1) . The body weight difference between the B6 and the ␤-gal Ϫ/Ϫ mice may result from either maternal or strain differences. Furthermore, no differences were found between the control and the treated mice, either B6 or ␤-gal Ϫ/Ϫ , for eye opening (p-14 to p-15) or righting reflex at p-15. Although C-BS and cerebellar GM1 content was significantly greater in the mutant ␤-gal Ϫ/Ϫ mice than in the normal B6 mice, no histological evidence of ganglioside storage material or neuronal vacuoles was seen in the p-15 ␤-gal Ϫ/Ϫ mice by light microscopy after LFB staining of paraffin-embedded brain tissue (Fig. 1) . Also, no ganglioside storage was seen after PAS staining of serial brain sections (data not shown).
The influence of NB-DGJ on the qualitative and quantitative distribution of C-BS and cerebellar gangliosides is shown in Fig. 2 and Table 2 . Gangliosides that were absent or that constituted less than 1% of the total distribution [GM4, GM3, and GM2 in all regions, and II 3 (NeuAc) 2 -LacCer (GD3) in the ␤-gal Ϫ/Ϫ C-BS] were omitted from the computations. In contrast to the C-BS, where GM1 is a major ganglioside, GM1 was a minor ganglioside in the cerebellum of normal B6 mice at p-15 (Table 2 ). This is consistent with previous observations in normal mice (29, 47) . However, GM1 was ‫-4ف‬fold greater in the C-BS and ‫-5ف‬ fold greater in the cerebellum of the untreated ␤-gal Ϫ/Ϫ mice than in the untreated B6 mice (Table 2) . NB-DGJ significantly reduced C-BS and cerebellar GM1 content by 18% and 17%, respectively, in the B6 mice and by 35% and 41%, respectively, in the ␤-gal Ϫ/Ϫ mice. Furthermore, NB-DGJ significantly reduced cerebellar GD3 content by ‫%05ف‬ in the B6 mice and by ‫%44ف‬ in the ␤-gal Ϫ/Ϫ mice ( Table 2 ). Other gangliosides (GD1a, GT1a/LD1, GD1b, and GT1b) were also reduced in either the C-BS or the cerebellum of the NB-DGJ-treated B6 and ␤-gal Ϫ/Ϫ mice ( Table 2 ). In contrast to most other gangliosides, NB-DGJ had no significant effect on C-BS or cerebellar GQ1b content in either the normal or the mutant mice.
The qualitative distribution of neutral lipids in the C-BS and cerebellum of p-15 B6 and ␤-gal Ϫ/Ϫ mice is shown in Fig. 3 . NB-DGJ had no obvious effect on the content or distribution of neutral lipids, including cholesterol, ceramide, cerebrosides, phosphatidylethanolamine, phosphatidylcholine, and GA1, in the C-BS and cerebellum of the B6 and ␤-gal Ϫ/Ϫ mice. The cerebrosides migrated as prominent double bands on the chromatogram and were more heavily expressed in cerebellum than in the C-BS. Sphingomyelin content in the C-BS and in the cerebellum was significantly increased by 42% and 12%, respectively, in the treated B6 mice, and by 31% and 18%, respectively, in the ␤-gal Ϫ/Ϫ mice ( Table 3) . Also, sphingomyelin content was generally higher in the cerebellum than in the C-BS of the normal and mutant mice. Although absent in the normal B6 CNS, GA1 accumulated in the CNS of the ␤-gal Ϫ/Ϫ mice, and accumulation was greater in the C-BS than in the cerebellum (Table 3) . NB-DGJ treatment had no significant effect on GA1 content in either brain region. Cerebrosides in the B6 mice and cerebrosides and GA1 in the ␤-gal Ϫ/Ϫ mice were the only neutral GSLs detectable in the C-BS or cerebellum.
To determine whether ganglioside synthesis inhibition influenced cerebellar development, we examined cerebellar morphology and the thickness of the EGL in control and NB-DGJ-treated ␤-gal Ϫ/Ϫ mice (Fig. 4) . Cerebellar morphology was similar in the control and treated ␤-gal Ϫ/Ϫ mice. Also, no differences were found between the control and treated ␤-gal Ϫ/Ϫ mice for EGL thickness in vernal lobule VI (14.5 Ϯ 0.4 and 13.7 Ϯ 0.6 m, respectively) or in vernal lobule X (20.3 Ϯ 1.3 and 19.6 Ϯ 1.1 m, respectively). These data indicate that NB-DGJ treatment does not alter granule cell migration in the cerebellum and are consistent with behavioral evidence that NB-DGJ does not alter ambulation or righting reflex. Additionally, cerebellar morphology and EGL thickness were similar in untreated B6 and ␤-gal Ϫ/Ϫ mice at p-15.
DISCUSSION
In our previous study, we showed that N B-DGJ could significantly reduce total brain and GM1 content when administered from p-2 to p-5 in control B6 and mutant ␤-gal Ϫ/Ϫ mice (3). The p-2 to p-5 neonatal ages in mice are comparable to prenatal ages in humans as they precede the period of active brain myelinogenesis and cerebellar development. Moreover, the reduction in CNS ganglioside content had no adverse effects on development. It was not known from this study, however, whether NB-DGJ treatment could also be effective at older ages, especially during critical stages of cerebellar development and myelinogenesis. No previous studies have examined the effects of this drug on CNS lipids during these developmental ages. It was also not known whether the neonatal mice could tolerate NB-DGJ injections for 7 days during this critical period. In the present study, we found that NB-DGJ treatment from p-9 to p-15 significantly reduced total ganglioside and GM1 content both in the C-BS and in the developing cerebellum of normal B6 and mutant ␤-gal Ϫ/Ϫ mice, indicating a CNS-wide effect. Moreover, these reductions in ganglioside content had no obvious adverse effects on behavior or CNS development.
We found that NB-DGJ significantly reduced total ganglioside and GD3 content in the cerebellum of ␤-gal Ϫ/Ϫ mice without altering morphology or the thickness of the EGL. GD3 is enriched in vertebrate CNS neuroectodermal cells, including granule cells of the EGL, in the developing mouse cerebellum (29, (47) (48) (49) (50) (51) (52) (53) . Our findings indicate that inhibition of total ganglioside and GD3 biosynthesis did not affect the migration of granule cells from the EGL to the internal granular layer. These observations are consistent with previous findings that NB-DGJ-induced inhibition of ganglioside biosynthesis does not impair brain development in the organogenesis-stage mouse embryo (27) . Hence, NB-DGJ may be an effective early intervention therapy for ganglioside storage diseases during critical stages of brain development.
The amount of myelin in the brain is directly propor- tional to the concentration of cerebroside, a neutral GSL (30, 45, 54) . Myelination also occurs earlier in cerebellum than in cerebral cortex according to phylogenetic development (36) . We previously showed that the rate of cerebroside accumulation was greatest in B6 mice from p-14 to p-16 (30) . In addition to cerebroside, GM1 is also enriched in mammalian CNS myelin (30, (55) (56) (57) (58) . The amount of water in the brain is another factor associated with CNS myelin content, because myelin is dehydrated relative to gray matter (30, 36, 59) . Therefore, it would be important to determine whether ganglioside synthesis inhibition and GM1 reduction influenced myelinogenesis in normal and mutant mice. The prominent cerebroside doublet seen on HPTLC in both the C-BS and cerebellum is indicative of active myelinogenesis in the p-15 brains. Our data show that the content of CNS cerebrosides and water was not altered after NB-DGJ treatment in either B6 or ␤-gal Ϫ/Ϫ mice. These findings suggest that NB-DGJ treatment does not adversely affect myelinogenesis in the developing mouse CNS. Ceramide, sphingomyelin, and cerebroside are sphingolipids that could be influenced by NB-DGJ treatment (3, 27, 60) . We previously found increases of whole brain ceramide and sphingomyelin in neonatal mice treated with a high NB-DGJ concentration (1,200 mg/kg) from p-2 to p-5 (3). In the present study, we found that sphingomyelin was the only CNS neutral lipid significantly increased in the p-15 treated mice. The sphingomyelin increase might be a compensatory response to an increase of ceramide that we observed previously in mice treated from p-2 to p-5 (3). This would be reasonable, because ceramide is a precursor for sphingomyelin synthesis. Moreover, it would be important to maintain low levels of ceramide because ceramide has been implicated in neural cell apoptosis (27, 61) . NB-DGJ treatment had no significant effect on the distribution of other major CNS neutral lipids. These findings, viewed together with the ganglioside analysis, suggest that NB-DGJ primarily reduces ganglioside content and has little effect on most major CNS neutral lipids. We do not exclude the possibility that NB-DGJ might influence the CNS distribution of minor neutral GSLs (e.g., glucosylceramide, lactosylceramide, or globoside), but these lipids were undetectable in either the C-BS or the cerebellum.
Extensive CNS storage of PAS-positive material and neuronal vacuoles occurs by ‫5ف‬ weeks of age in the ␤-gal Ϫ/Ϫ mice (2) . Previous studies with another ␤-gal Ϫ/Ϫ mouse model showed CNS storage material between 2 and 3 weeks of age (62) . Despite significant increases of GM1, we were unable to detect neuronal vacuoles or lipid storage material in either the C-BS or the cerebellum using LFB or PAS in p-15 ␤-gal Ϫ/Ϫ mice. These findings indicate that biochemical ganglioside accumulation in this mouse model has not reached the point of clear histological detection by p-15. Consequently, it was not possible to determine if NB-DGJ treatment could reduce CNS storage material or neuronal vacuoles. Based on our current findings and those of our previous study in p-5 mice, we suggest that NB-DGJ could be used to target ganglioside accumulation during the entire period of postnatal development. Further studies in older mutant mice that were treated throughout development could determine whether the NB-DGJinduced reductions in CNS GM1 content are associated with reductions in CNS storage material and neuronal vacuoles.
In contrast to our previous findings in mutant ␤-gal Ϫ/Ϫ mice at p-5, NB-DGJ treatment did not increase CNS GA1 content in the mutants at p-15. A lower NB-DGJ concentration used in this study (600 mg/kg vs. the 1,200 mg/kg used in the previous study) may account for the difference. It is also important to note that CNS GA1 content is proportionally greater in the mouse than in the human forms of the disease, possibly as a result of a more active sialidase in the mouse (2, 63, 64) . Assuming that CNS GA1 in the mutant mouse is derived largely from GM1 desialylation, it is interesting that NB-DGJ treatment, which reduced GM1 content, did not also reduce GA1 content. Recent studies showed that NB-DGJ could enhance lysosomal enzyme activity through chaperone effects (7, 65) . Further studies will be needed to assess possible NB-DGJ chaperone effects and the relationship between GM1, GA1, and sialidase activity in the control and NB-DGJ-treated ␤-gal Ϫ/Ϫ mice.
In summary, our results show that NB-DGJ reduces C-BS and cerebellar total ganglioside and GM1 content in normal B6 and ␤-gal Ϫ/Ϫ mice during critical stages of CNS development. Moreover, these ganglioside reductions had no observable adverse effects on behavior or CNS development. These findings, together with our previous observations in p-5 mice, suggest that NB-DGJ may be an effective early intervention therapy for ganglioside storage diseases and should have translational benefit to the clinic. This work was supported by the Boston College Research Expense Fund, grants from the National Institutes of Health (HD-39722) and the National Tay-Sachs and Allied Disease Association, Inc., and the Burroughs Wellcome Fund. The authors thank Rena Baek, Christine Denny, and Lisa Mahoney for technical assistance.
